<DOC>
	<DOCNO>NCT00287755</DOCNO>
	<brief_summary>To evaluate usefulness chemosensitivity test evaluate appropriate adjuvant cancer chemotherapy gastric surgery</brief_summary>
	<brief_title>Clinical Trial Chemosensitivity Test</brief_title>
	<detailed_description>Patients : clinical Stage III gastric cancer patient . Informed consent obtain surgery . Eligible patient : surgical Stage II , IIIA IIIB gastric cancer patient . Chemosensitivity test : The surgical specimen send Mitsubishi BCL , Co. Ltd. test CD-DST chemosensitivity test RT-PCR thymidylate synthetase dihydropyrimidine dehydrogenase mRNA . The test result blind doctor duty . Treatment : All patient treat S-1 dose 80 mg/m2 b.i.d . 4 week follow 2 week rest . The treatment continue recurrence 1 year operation . Primary endpoint : 3-years disease-free survival rate Secondary endpoint : 3-years overall survival rate side effect ( CTCAE v3.0 ) Evaluation chemosensitivity test : The cutoff condition determine base accumulate data CD-DST mRNAs . Hypothesis : The responder detect CD-DST and/or TS , DPD mRNA favorable survival outcome compare resistant case .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>histologically proven gastric cancer PS ( ECOG ) 0 2 D2 dissection , curability B surgical Stage IIIA IIIB negative peritoneal cytology previous radiotherapy , chemotherapy hormone therapy possible peroral intake 6 POW severe surgical complication normal bone marrow , liver renal function complete chemosensitivity test write informed consent multiple cancer contraindication S1 history drug allergy ( grade 3 ) severe complication watery diarrhea pregnant scirrhous gastric cancer patient judge inadequate trial doctor duty</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>gastric cancer</keyword>
	<keyword>S-1</keyword>
	<keyword>chemosensitivity</keyword>
	<keyword>adjuvant</keyword>
</DOC>